Navigating antiphospholipid syndrome: from personalized therapies to cutting-edge research.

IF 2.1 Q3 RHEUMATOLOGY

Rheumatology Advances in Practice Pub Date : 2025-01-08 eCollection Date: 2025-01-01 DOI:10.1093/rap/rkaf005

Karen Kortright-Maldonado, Bruno Eduardo Reyes-Torres, Lilian Stephany Cabrera-Lopez, Pedro Rodríguez-Henríquez, Erika Karina Tenorio-Aguirre, Froylan D Martínez-Sánchez

{"title":"Navigating antiphospholipid syndrome: from personalized therapies to cutting-edge research.","authors":"Karen Kortright-Maldonado, Bruno Eduardo Reyes-Torres, Lilian Stephany Cabrera-Lopez, Pedro Rodríguez-Henríquez, Erika Karina Tenorio-Aguirre, Froylan D Martínez-Sánchez","doi":"10.1093/rap/rkaf005","DOIUrl":null,"url":null,"abstract":"<p><p>APS is an autoimmune disorder characterized by thrombosis and pregnancy complications, primarily driven by aPLs such as LA, aCL and anti-β2 glycoprotein I (a-β2GPI). Despite advances in anticoagulation therapies, managing refractory APS cases remains challenging. Emerging therapies, including rituximab, eculizumab and HCQ, show potential in addressing the underlying mechanisms of APS. Additionally, research into genetic and environmental factors, particularly the gut microbiome's role through molecular mimicry, suggests new therapeutic pathways. Diagnostic advancements, such as the adjusted Global Antiphospholipid Syndrome Score (aGAPSS), metabolomic profiling and MRI, have improved risk stratification and early detection. Non-traditional biomarkers like anti-phosphatidylserine/prothrombin (aPS/PT) and anti-Domain I antibodies further enhance risk assessment. Future research should aim to validate these approaches, optimizing patient outcomes and minimizing long-term APS complications.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"9 1","pages":"rkaf005"},"PeriodicalIF":2.1000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11751690/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology Advances in Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/rap/rkaf005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

APS is an autoimmune disorder characterized by thrombosis and pregnancy complications, primarily driven by aPLs such as LA, aCL and anti-β2 glycoprotein I (a-β2GPI). Despite advances in anticoagulation therapies, managing refractory APS cases remains challenging. Emerging therapies, including rituximab, eculizumab and HCQ, show potential in addressing the underlying mechanisms of APS. Additionally, research into genetic and environmental factors, particularly the gut microbiome's role through molecular mimicry, suggests new therapeutic pathways. Diagnostic advancements, such as the adjusted Global Antiphospholipid Syndrome Score (aGAPSS), metabolomic profiling and MRI, have improved risk stratification and early detection. Non-traditional biomarkers like anti-phosphatidylserine/prothrombin (aPS/PT) and anti-Domain I antibodies further enhance risk assessment. Future research should aim to validate these approaches, optimizing patient outcomes and minimizing long-term APS complications.

查看原文本刊更多论文

导航抗磷脂综合征：从个性化治疗到前沿研究。

APS是一种以血栓形成和妊娠并发症为特征的自身免疫性疾病，主要由LA、aCL和抗β2糖蛋白I （a-β2GPI）等api驱动。尽管抗凝治疗取得了进展，但治疗难治性APS病例仍然具有挑战性。新兴疗法，包括利妥昔单抗、eculizumab和HCQ，显示出解决APS潜在机制的潜力。此外，对遗传和环境因素的研究，特别是肠道微生物组通过分子模拟的作用，提出了新的治疗途径。诊断方面的进步，如调整后的全球抗磷脂综合征评分（aGAPSS）、代谢组学分析和MRI，改善了风险分层和早期发现。非传统生物标志物，如抗磷脂酰丝氨酸/凝血酶原（aPS/PT）和抗结构域I抗体进一步加强了风险评估。未来的研究应旨在验证这些方法，优化患者预后并最大限度地减少APS的长期并发症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊